Cinacalcet Tablets Recalled for cGMP Deviations
Cipla USA, Inc. is recalling Cinacalcet Hydrochloride Tablets, 60 mg due to cGMP deviations involving the presence of N-nitroso-cinacalcet above acceptable daily intake levels.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall involving a prescription drug with a potential safety concern (N-nitroso impurity above acceptable intake levels). Class II recalls with pharmaceutical safety hazards warrant a Severe classification per the rubric.
Plain-English summary
Cipla USA, Inc. is recalling Cinacalcet Hydrochloride Tablets, 60 mg (30-count bottles, NDC 69097-411-02) distributed nationwide. The recall is due to cGMP deviations: the presence of N-nitroso-cinacalcet in the product at levels above the acceptable daily intake (ADI).
The affected lots are 5PB0165 and 5PB0166 (expiration 1/31/2027); 5PB0552 (expiration 4/30/2027); and 5PB0642, 5PB0643, and 5PB0644 (expiration 6/30/2027). Cinacalcet is a prescription medication used to treat hyperparathyroidism.
Consumers who have this medication should contact their healthcare provider or pharmacist for guidance. Do not discontinue use of the medication without consulting a healthcare professional.
The recalled product
- Product
- CINACALCET (CINACALCET)
- Brand
- CINACALCET
- Manufacturer
- Cipla USA, Inc.
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- Lot #: 5PB0165
- 5PB0166
- Exp 1/31/2027
- 5PB0552
- Exp 4/30/2027
- 5PB0642
- 5PB0643
- 5PB0644
- Exp 6/30/2027
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Cipla USA, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same brand · CINACALCET
- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-07-08
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighCipla cinacalcet 60 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 30 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 90 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
Same manufacturer · Cipla USA, Inc.
See all →- HighCipla lanreotide prefilled syringes recalled over visual inspection deficiencies
FDA (Drugs) · 2026-04-15
- HighCipla lanreotide syringes with safety needle recalled over sterility assurance
FDA (Drugs) · 2026-04-15
Same hazard · n nitroso impurity
See all →- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29
- SevereFluoxetine Tablets 20 mg Recalled for N-Nitroso Impurity
FDA (Drugs) · 2025-06-11
- SevereCarvedilol Tablets Recalled Due to N-Nitroso Impurity
FDA (Drugs) · 2025-06-04
- HighDuloxetine Delayed-Release Capsules Recalled for N-Nitroso Impurity Above Safe Levels
FDA (Drugs) · 2025-03-26